355 related articles for article (PubMed ID: 33472320)
1. [Progress of PD-1/PD-L1 inhibitors in the treatment of small-cell lung cancer].
Zhang SY; Wang Y
Zhonghua Zhong Liu Za Zhi; 2021 Jan; 43(1):98-103. PubMed ID: 33472320
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of PD-1/PD-L1 inhibitor plus chemotherapy versus chemotherapy alone as first-line treatment for extensive-stage small cell lung cancer: A systematic review and meta-analysis.
Zhang S; Li S; Cheng Y
Thorac Cancer; 2020 Dec; 11(12):3536-3546. PubMed ID: 33058504
[TBL] [Abstract][Full Text] [Related]
3. Use of Immunotherapy in Extensive-Stage Small Cell Lung Cancer.
Konala VM; Madhira BR; Ashraf S; Graziano S
Oncology; 2020; 98(11):749-754. PubMed ID: 32663833
[TBL] [Abstract][Full Text] [Related]
4. Beyond Programmed Death-Ligand 1: B7-H6 Emerges as a Potential Immunotherapy Target in SCLC.
Thomas PL; Groves SM; Zhang YK; Li J; Gonzalez-Ericsson P; Sivagnanam S; Betts CB; Chen HC; Liu Q; Lowe C; Chen H; Boyd KL; Kopparapu PR; Yan Y; Coussens LM; Quaranta V; Tyson DR; Iams W; Lovly CM
J Thorac Oncol; 2021 Jul; 16(7):1211-1223. PubMed ID: 33839362
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and Safety of PD-1/PD-L1 Inhibitor Chemotherapy Combined with Lung Cancer Fang No. 1 in Relapsed and Refractory SCLC: A Retrospective Observational Study.
Wang L; Lei X; Wang X
Comput Math Methods Med; 2022; 2022():2848220. PubMed ID: 35586668
[TBL] [Abstract][Full Text] [Related]
6. [Therapeutic efficacy analysis of immunotherapy in small cell lung cancer].
Zhong J; Zheng QW; Zhao J; Wang ZP; Wu MN; Zhuo ML; Wang YY; Li JJ; Yang X; Chen HX; An TT
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):771-776. PubMed ID: 32988161
[No Abstract] [Full Text] [Related]
7. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
Xia L; Liu Y; Wang Y
Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
[TBL] [Abstract][Full Text] [Related]
8. Prolonging Survival: The Role of Immune Checkpoint Inhibitors in the Treatment of Extensive-Stage Small Cell Lung Cancer.
Melosky B; Cheema PK; Brade A; McLeod D; Liu G; Price PW; Jao K; Schellenberg DD; Juergens R; Leighl N; Chu Q
Oncologist; 2020 Nov; 25(11):981-992. PubMed ID: 32860288
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of anlotinib combined with PD-1/PD-L1 inhibitors as second-line and subsequent therapy in advanced small-cell lung cancer.
Yu L; Xu J; Qiao R; Han B; Zhong H; Zhong R
Cancer Med; 2023 Mar; 12(5):5372-5383. PubMed ID: 36250532
[TBL] [Abstract][Full Text] [Related]
10. [Research progress of immune checkpoint inhibitors in clinical diagnosis and treatment of non-small cell lung cancer].
Huang Y; Xu K; Wang W; Cui F; Zeng Y; Hao ZX; Cai WP; He JX; Liu J
Zhonghua Zhong Liu Za Zhi; 2020 Sep; 42(9):713-717. PubMed ID: 32988151
[TBL] [Abstract][Full Text] [Related]
11. [Clinical Research Progress of Immune Checkpoint Inhibitors in the Treatment of
Small Cell Lung Cancer].
Huang B; Duan Y
Zhongguo Fei Ai Za Zhi; 2019 Apr; 22(4):239-244. PubMed ID: 31014443
[TBL] [Abstract][Full Text] [Related]
12. [Progress in Clinical Researches of PD-1/PD-L1 Checkpoint Inhibitor for Non-small Cell Lung Cancer].
Wu S; Hu C; Wu F; Wu Y; Liu P
Zhongguo Fei Ai Za Zhi; 2019 Jul; 22(7):440-448. PubMed ID: 31315783
[TBL] [Abstract][Full Text] [Related]
13. [Clinical Development of Immunotherapy for Small Cell Lung Cancer].
Yu T; Zhong D
Zhongguo Fei Ai Za Zhi; 2018 Dec; 21(12):918-923. PubMed ID: 30591100
[TBL] [Abstract][Full Text] [Related]
14. Targeted Therapy and Immune Therapy for Small Cell Lung Cancer.
Gadgeel SM
Curr Treat Options Oncol; 2018 Sep; 19(11):53. PubMed ID: 30203184
[TBL] [Abstract][Full Text] [Related]
15. Anti-PD-L1 immune checkpoint inhibitors in combination with etoposide and platinum for extensive-stage small cell lung cancer: a case report.
Xue L; Chen B; Lin J; Peng J
Ann Palliat Med; 2021 Jan; 10(1):828-835. PubMed ID: 33545805
[TBL] [Abstract][Full Text] [Related]
16. The Future of Immunotherapy in the Treatment of Small Cell Lung Cancer.
Horn L; Reck M; Spigel DR
Oncologist; 2016 Aug; 21(8):910-21. PubMed ID: 27354668
[TBL] [Abstract][Full Text] [Related]
17. [Progress on PD-1/PD-L1 Checkpoint Inhibitors in Lung Cancer].
Zhang D; Huang J; Zhang C; Guan Y; Guo Q
Zhongguo Fei Ai Za Zhi; 2019 Jun; 22(6):369-379. PubMed ID: 31196371
[TBL] [Abstract][Full Text] [Related]
18. Immune-checkpoint inhibitors plus chemotherapy versus chemotherapy as first-line treatment for patients with extensive-stage small cell lung cancer.
Zhou F; Zhao W; Gong X; Ren S; Su C; Jiang T; Zhou C
J Immunother Cancer; 2020 Sep; 8(2):. PubMed ID: 32900864
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers.
Medjebar S; Truntzer C; Perrichet A; Limagne E; Fumet JD; Richard C; Elkrief A; Routy B; Rébé C; Ghiringhelli F
Oncoimmunology; 2020 Oct; 9(1):1836766. PubMed ID: 33178495
[TBL] [Abstract][Full Text] [Related]
20. Benefits and risks of PD-1/PD-L1 inhibitors for recurrent small cell lung cancer: A systematic review and meta-analysis.
Zhou J; Du Z; Liang Y; Zhang S
Crit Rev Oncol Hematol; 2024 Jan; 193():104222. PubMed ID: 38036155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
